Clinical trial · Observational
A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting
Prospective Assessment of Dasatinib Management Among CP-CML Patients With Dasatinib Initiation in a Real Life Setting: DasaREALISE.
NCT04089839CI-TRIAL-00059187completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, non-interventional study conducted in CP-CML patients receiving dasatinib who are enrolled by a sample of hematologists in France.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- CP-CML participants initiating dasatinib
- interventionNames
- Other: Non-Interventional
Primary outcomes (1)
- measure
- Incidence of CP-CML patients remaining on dasatinib treatment
- timeFrame
- 24 months
Secondary outcomes (20)
- measure
- Distribution of median age of CP-CML patients receiving dasatinib
- timeFrame
- 24 months
- measure
- Distribution of sex ratio of CP-CML patients receiving dasatinib
- timeFrame
- 24 months
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged greater than or equal to 18 years * Patients diagnosed with CP-CML * Patients who started dasatinib within the last month before inclusion, or on the day of inclusion or within the month after inclusion Exclusion Criteria: * Patients participating in an ongoing interventional trial * Patients diagnosed with AP-CML (accelerated phase) or BP-CML (blast phase)
References
Publications (0)
Data not yet available
No reference posted for this study.